The iOTA-SMI program represents a novel approach to obesity management in a high-need population, addressing a significant gap in effective treatments for obesity among individuals with serious mental illness. Given the high prevalence of obesity in this demographic and the lack of FDA-approved pharmacotherapies, the program could capture a unique market segment. The competitive landscape includes traditional behavioral interventions and off-label pharmacotherapies, which have shown limited effectiveness. The scalability and adaptability of the iOTA-SMI program may enhance its attractiveness for potential partnerships or funding opportunities, particularly in community mental health settings. Future effectiveness testing and large-scale dissemination could further validate its commercial viability.